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Introduction
Use of HRT by postmenopausal women is associated
with an increased risk for breast cancer by a factor of
1.02 for each year of use (10% develop breast cancer
after 5 years of HRT use) [1]. The expression of ER-α
appears to increase in the normal breast tissue of post-
menopausal women who use HRT [2]. High BMI (BMI =
weight in kilograms/[height in metres]2) is also associ-
ated with elevated risk for postmenopausal breast
cancer [3]. Accordingly, it is of interest to determine
whether there is any association between BMI and ER-α
expression in normal breast epithelial cells in normal pre-
menopausal and postmenopausal women, who do not
have breast or other cancers and who are current users
and nonusers of HRT.
Patients and method
Samples of breast tissue were collected from the archives of
the Department of Anatomical Pathology at St Vincent’s
Hospital in Sydney, Australia. The samples had been
obtained by open surgical and core biopsy from 32 pre-
menopausal and 21 postmenopausal Caucasian Australian
women, who had had biopsies taken in order to exclude
breast cancer and for whom data regarding age,
menopausal status, use of HRT, height and weight were
available. The participants were recruited serially by going
backwards in time from the most recent date of collection.
The number of participants was dependent on the availability
of specimens and relevant data. Only two out of the 32 pre-
menopausal women were currently using hormone contra-
ceptives. These premenopausal women were analyzed as a
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Abstract
Background: It is known that use of hormone replacement therapy (HRT) by postmenopausal women
increases the risk of breast cancer.
Method: In this study, oestrogen receptor (ER)-α expression is examined using standard immuno-
peroxidase technique.
Results: Normal breast samples of 11 Australian postmenopausal women have been included in the
ER-α study; the result showed a strong correlation (r2 = 0.80) between ER-α expression in normal
breast epithelial cells and body mass index (BMI) in normal women who currently use HRT.
Conclusion: This finding confirms that the possibility of increased risk of breast cancer associated with
increased ER-α expression in normal breast epithelial cells, in turn associated with high BMI and the
use of HRT.
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single group. Eleven out of the twenty-one postmenopausal
women were currently using HRT. These latter women were
analyzed in two groups according to current use of HRT.
All biopsies had yielded benign, nonproliferative breast
tissue. None of the women had breast or other cancers.
Only normal breast epithelium regions, specifically the
lobular unit, were considered for the present study. The
breast tissue samples were fixed at room temperature in
buffered 10% formalin and were paraffin embedded in one
laboratory. The subsequent processing and staining of the
samples was undertaken by one investigator (DDT). ER
immunohistochemistry assays using anti-ER-α antibody
Dako 1D5 and counts of breast epithelial cells were con-
ducted as previously reported [4].
Pearson’s correlation coefficient is indicated by ‘r2’. A cor-
relation coefficient in the range 0–1 indicates a positive
correlation, with 1 representing the strongest correlation;
a negative correlation is indicated by a negative value.
Results
The results are shown in Fig. 1 and Table 1. There was a
positive correlation (r2 = 0.80; P = 0.003) between BMI and
ER-α expression among postmenopausal women who were
currently using HRT. There was no correlation between BMI
and ER-α expression in postmenopausal women who were
not currently using HRT (r2 = –0.33; not significant). There
were no correlations between BMI and ER-α expression in
premenopausal women (r2 = –0.17; not significant). The
average percentage of breast epithelial cells that showed
positive ER-α expression was significantly higher in both
postmenopausal HRT users and nonusers, as compared
with premenopausal women (P = 0.001).
Discussion
The number of participants included in the present study is
clearly small, and therefore the findings should be consid-
ered with caution. The correlation between ERα expression
and BMI in postmenopausal women currently using HRT,
however, is striking and is highly statistically significant.
We showed in normal breast epithelial cells of normal
women without breast cancer that there is higher ER-α
expression in postmenopausal women than in pre-
menopausal women, whether or not they are users of
HRT; that the average levels of ER-α expression in post-
menopausal women are similar, whether or not they are
users of HRT; and that there is a marked increase in levels
of ER-α expression in users of HRT who are overweight.
The apparent contradiction of the second and third find-
ings is due to the clustering of ER-α expression levels
around the mean among nonusers of HRT, in contrast to
the marked increase in ER-α levels of expression with
increased BMI among users of HRT.
Table 1
ER-α α positivity among Australian premenopausal and postmenopausal women
Average Correlation  (r2) between 
Average age  Average BMI percentage of BMI and percentage of 
(years) (kg/m2) ER-α-positive cells ER-α-positive cells
Premenopausal (n = 32) 37.5 22.2 15.3 –0.17 (NS)
Postmenopausal
No HRT (n = 11) 55.5 22.3 24.4 –0.33 (NS)
HRT (n = 11) 60.1 25.0 22.1 0.80 (P = 0.003)
Percentage of ER-α-positive normal breast epithelial cells in Australian pre- and postmenopausal women, correlated with height, BMI and use of
HRT. A BMI of 25 or over suggests excess weight. NS, not significant at 95% confidence; P, two-tailed t-test at 95% confidence.
Figure 1
ER expression in normal breast epithelial cells and BMI of Australian
women using HRT.Breast Cancer Research    Vol 3 No 5 Lawson et al
It is probable that there is a reciprocal relationship
between ER-α expression and levels of serum oestrogens,
with high ER-α expression occurring in the presence of
low levels of serum oestrogens, and vice versa [5–8].
ER-α expression in breast epithelial cells and serum
oestrogen levels, however, are likely to have a more
complex relationship than a simple reciprocal one. For
example, use as compared with nonuse of exogenous
estrogens (ie HRT) by postmenopausal women leads to a
threefold increase in serum oestradiol and to a sixfold
increase in serum oestrones [9]. Accordingly, in the pres-
ence of such high serum oestrogen levels in users of HRT,
it would be expected that there would be low ER-α
expression. As shown in this and other studies [2],
however, use of HRT by postmenopausal women does not
result in the expected reduction in ER-α expression.
Obesity or alterations in weight further complicate the
underlying physiology in both premenopausal and post-
menopausal women. Obesity in premenopausal women
appears to reduce serum oestradiol. This is possibly
because of reduced ovulation. Such obesity is associated
with a reduction in risk for breast cancer risk [3,10].
Obesity in postmenopausal women leads to increased
oestrogen formation from adipose tissues, and is associ-
ated with an increased risk for breast cancer [11]. Among
women who use HRT, however, the influence of obesity
on serum oestrogens is small compared with that of
exogenous oestrogens.
In addition and of great importance to our understanding
of breast cancer is that the presence of carcinogenic
processes can both subtlety and dramatically alter any
relationship between the expression of oestrogen recep-
tors and serum oestrogen levels. In the majority of women
who develop breast cancer, the proportion of breast
epithelial cells that show positive ER-α expression
increases in parallel with progression of carcinogenesis,
from hyperplasia of epithelial cells, to localized cancer and
finally to invasive cancer [12]. This shows that malignant
breast epithelial cells develop largely independent of
overall physiology.
It is possible that an increase in ER-α expression in normal
breast epithelial cells may be associated with increased
breast cancer risk. There are two lines of evidence that
support this. The first is the observation by Kahn et al [2]
that there is high ER-α expression in normal breast epithe-
lial cells in women with breast cancer. These observed dif-
ferences in receptor status may be influenced by the
breast cancer itself, however, such as intramural produc-
tion of oestrogen or growth factors. The second is the
observation that ER-α expression in normal breast epithe-
lial cells in normal Australian women is fivefold higher than
in their Japanese counterparts [4]. This high level of ER-α
expression parallels the threefold higher risk of breast
cancer in Australian as compared with Japanese women.
This latter observation confirms similar findings for
markedly differing levels of ER-α expression in normal
endometrial epithelial cells from normal Finnish and Japan-
ese women, which also parallels the differences in risk for
endometrial cancer [13].
Therefore, there is no satisfactory explanation for the find-
ings of the present study. Consideration of the underlying
mechanisms of steroid receptor activation and inactiva-
tion, and any hypotheses must be speculative [14]. We
speculate that, in an environment of HRT-induced pres-
ence of high levels of oestrogens, exacerbated by addi-
tional oestrogens sourced from adipose tissue in obese
women, ERs may become overstressed and cease to
function normally. Another possible explanation is the
development of a hypersensitive ER-α mutation [15].
Regardless of the mechanisms involved in the apparently
abnormal ER function observed in the present study, the
possibility exists of increased risk for breast cancer asso-
ciated with increased ER-α expression in normal breast
epithelial cells, in turn associated with high BMI and use of
HRT.
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